Gastrointestinal stromal tumors (GISTs) are a type of cancer that originates in the gastrointestinal tract, commonly in the stomach or small intestine. These tumors are characterized by mutations in genes such as KIT or PDGFRA and are typically treated with targeted therapies like imatinib (Gleevec) or sunitinib.
Blueprint Medicines Received FDA approval for Ayvakit® (avapritinib), a new oral, targeted therapy for patients with advanced GIST harboring PDGFRA D842 mutations, offering a new treatment option with potentially better tolerability than existing drugs.
Taiho Pharmaceutical Introduced Jeselhy® Tablets (rilapladimab) in Japan, an oral heat shock protein (HSP) 90 inhibitor for GIST that has progressed after chemotherapy, providing an alternative treatment pathway.
Agilent Technologies Developed a new line of eco-friendly flash chromatography solvents, aligning with the industry's sustainability initiatives and potentially impacting GIST research and drug development.
Thermo Fisher Scientific Acquired chromatography instrumentation company, Chemyx Inc., in 2023, strengthening its position in the flash chromatography market, a key technology used in GIST research and drug development.
Waters Corporation Collaborated with academic institutions to develop advanced flash chromatography applications for drug discovery and biopharmaceutical research, potentially benefiting GIST treatment development.
List of Gastrointestinal Stromal Tumors Key Companies in the Market
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)